Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Files for Initial Public Offering

Premium

Regulus Therapeutics, the microRNA drug joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has filed with US regulators to begin selling its shares on the public market.

The move to float its shares has been expected for some time, as Regulus in 2010 began looking to fill positions with duties related to the activities of a public company (GSN 9/23/2010).

In a filing with the US Securities and Exchange Commission last week, Regulus said it has signed on Lazard Capital Markets, Cowen and Company, and BMO Capital Markets to jointly manage the proposed initial public offering.

Specific details, including the number of shares to be offered, the price range of the offering, and when the IPO might occur were not provided.

In the filing, Regulus did provide a few details about its business plan, including its pipeline of miRNA-targeting drugs.

According to the company, it has five programs in development. The first targets miR-21 to treat liver cancer and is being developed in collaboration with Sanofi. It is also working with Sanofi on the same miRNA as a treatment for kidney fibrosis.

Regulus' most advanced effort is its hepatitis C program, which targets miR-122 and is being advanced with GlaxoSmithKline. It is also working with AstraZeneca on targeting miR-33 for atherosclerosis, and has an in-house program in glioblastoma that targets miR-10b.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.